Cortexin
What the Research Actually Shows
Human: 4 studies, 4 groups · Animal: 2 · In Vitro: 1
A cocktail of peptides extracted from cow and pig brains, prescribed across Russia for stroke and ADHD in children—where a systematic review found only one eligible trial and called the evidence "weak"
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
Cortexin is a mixture of small peptides extracted from the brain tissue of cattle or pigs. It is not a single defined drug—nobody knows exactly which molecules in the mixture are doing the work, or if the mixture is the same from batch to batch. It is widely prescribed in Russia for stroke recovery, ADHD in children, and cognitive decline. The largest study—635 children with attention and developmental problems—found improvements, but there was no placebo group and nobody was blinded. When an independent team reviewed all the evidence in 2021, they could find only one study (80 patients) that met basic quality standards. Their conclusion: the evidence is "weak" and the certainty is "low to very low." Cortexin may have real biological activity—it comes from the same intellectual tradition as Cerebrolysin—but the gap between how widely it is used and how little rigorous evidence exists is one of the largest in the nootropic space.
Cortexin belongs to a tradition of medicine that modern drug development has largely abandoned: tissue-specific peptide extracts. In the 1970s and 1980s, Russian scientist Vladimir Khavinson developed a theory of "bioregulation" proposing that each organ produces specific short peptides that regulate its function. Extract the peptides from a thymus, and you get an immune regulator (Thymalin). Extract them from the pineal gland, and you get a circadian regulator (Epithalamin). Extract them from the cerebral cortex, and you get a cognitive regulator—Cortexin.
Manufactured by Geropharm in St. Petersburg, Cortexin is a lyophilized extract of bovine or porcine cerebral cortex tissue containing a mixture of low-molecular-weight neuropeptides (under 10,000 daltons) and amino acids. It is administered by intramuscular injection—typically ten daily injections per treatment course—and is one of the most commonly prescribed neuroprotective agents in Russian clinical practice.
The evidence problem is severe. Cortexin has been prescribed to millions of patients across Russia and CIS countries, but the published evidence that would allow independent evaluation of its efficacy is almost nonexistent by Western standards. A 2021 systematic review surveying all available clinical evidence found only one study that met basic inclusion criteria. The review concluded with a verdict that should give any prescriber pause: "supporting evidence is weak," certainty is "low to very low," and effects are "probably less than would be considered clinically relevant."
In This Article
Quick Facts: Cortexin at a Glance
Type
Polypeptide mixture—lyophilized extract of bovine or porcine cerebral cortex tissue
Also Known As
Cortexinum, brain cortex cytomedine
Generic Name
Cortexin (not a single compound—a standardized tissue extract)
Brand Name
Cortexin® (Geropharm, St. Petersburg, Russia)
Molecular Weight
Mixture: peptide fraction ≤10 kDa; variable amino acid content
Peptide Sequence
Not applicable—complex, uncharacterized mixture of brain-derived peptide fragments
Endogenous Origin
Bovine or porcine cerebral cortex tissue—contains fragments of endogenous brain peptides and proteins, though specific active components have not been identified
Primary Molecular Function
Proposed: multi-receptor neuropeptide modulation (AMPA, kainate, mGluR, GABA receptors), neurotrophic support, antioxidant, anti-apoptotic—attributed to the whole extract, not identified peptides
Active Fragment
Unknown. Proteomic analysis identified β5-tubulin, creatine kinase B, and protein 14-3-3 α/β as molecular partners (PMID 30499504), but the specific active peptides have not been isolated.
Related Compound
Cerebrolysin is a similar brain-derived peptide extract from EVER Neuro Pharma (Austria), using whole porcine brain rather than cortex specifically. Cerebrolysin has a much larger clinical trial portfolio.
Clinical Programs
Widely prescribed in Russia/CIS for post-stroke cognitive recovery, ADHD, pediatric neurodevelopmental disorders, cognitive decline. No Western clinical trials.
WADA Status
Not prohibited
Community Interest
Cognitive enhancement, post-stroke recovery, ADHD support, general neuroprotection. Obtained from Russian pharmacy vendors and nootropic suppliers.
Route
Intramuscular injection (lyophilized powder reconstituted in saline or procaine)
FDA Status
Not approved. No FDA submission. No IND filed.
Half-Life
Not characterized (mixture—single-compound PK not applicable)
Evidence Tier
3 Pilot / Limited Human Data
Verdict
Eyes Open
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is Cortexin?
Pronunciation: KOR-tex-in
Your cerebral cortex—the folded outer layer of the brain responsible for thought, language, memory, and consciousness—is built from billions of neurons communicating through a dense network of peptide signals. These neuropeptides regulate everything from synaptic plasticity to neuronal survival. Cortexin attempts to capture those signals by extracting them directly from cortical tissue.
The manufacturing process takes bovine or porcine cerebral cortex, subjects it to enzymatic and acid hydrolysis, and extracts the low-molecular-weight fraction (peptides under 10,000 daltons) along with free amino acids. The result is a lyophilized powder that is reconstituted and injected intramuscularly. The concept is identical to Cerebrolysin's—take brain tissue, break it into small fragments that can cross the blood-brain barrier, and inject them on the hypothesis that brain-derived peptides will exert brain-beneficial effects.
PLAIN ENGLISH
Cortexin is made from the outer layer of cow or pig brains, broken down into tiny protein fragments and injected into muscle. The idea is that these brain fragments contain the natural signals that keep brain cells healthy. The problem is that nobody has figured out which specific fragments in the mixture are actually doing anything—or if the mixture is the same every time.
The difference between Cortexin and Cerebrolysin is specificity of source tissue and manufacturer. Cerebrolysin (EVER Neuro Pharma, Austria) uses whole porcine brain. Cortexin (Geropharm, Russia) uses cortex specifically, following Khavinson's organ-specific bioregulator philosophy. Cerebrolysin has a vastly larger clinical trial portfolio. Both share the same fundamental limitation: they are undefined mixtures whose active components have not been identified.
Origins and Discovery
Cortexin emerged from the Soviet bioregulator tradition—a research program led by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology beginning in the 1970s. Khavinson's central hypothesis was that each organ produces specific short peptides ("cytomedins") that regulate its function, and that administering organ-specific peptide extracts could restore physiological regulation in aging or disease.
This hypothesis produced a family of tissue extracts: Thymalin (thymus → immune regulation), Epithalamin (pineal gland → circadian/aging regulation), Retinalamin (retina → visual function), and Cortexin (cerebral cortex → cognitive/neuroprotective function). Each was developed through the Russian regulatory system, and several achieved widespread prescription use in Russia and CIS countries.
Cortexin is manufactured by Geropharm, a St. Petersburg pharmaceutical company closely associated with the Khavinson research tradition. It has been prescribed in Russia for decades for stroke rehabilitation, pediatric cognitive and neurodevelopmental disorders (including ADHD and speech delay), traumatic brain injury, and age-related cognitive decline.
The bioregulator tradition represents a fundamentally different approach to drug development than Western pharmaceutical science. Where Western science begins with a defined molecule, studies its mechanism, tests it in controlled trials, and seeks regulatory approval, the bioregulator approach begins with a biological hypothesis (organ-specific peptide regulation), produces a complex mixture, observes clinical effects, and refines the therapy empirically. Both approaches can produce therapeutically active products—but only one produces the kind of evidence that modern regulatory systems accept.
Mechanism of Action
The Undefined Mixture Problem
Cortexin's mechanism cannot be described with the precision of a single-molecule drug because Cortexin is not a single molecule. Every mechanistic claim is attributed to the whole extract, not to identified active components.
Proposed Neurotrophic Activity
Manufacturer and published research propose that Cortexin peptides support neuronal survival, axonal growth, and synaptic plasticity through neurotrophic factor-like signaling. This is plausible—brain-derived peptide fragments could include sequences with neurotrophic activity—but the specific peptides responsible have not been isolated or characterized.
Receptor Modulation
In vitro studies from Geropharm preclinical data show Cortexin peptides interact with AMPA, kainate, mGluR1, GABAA1, and mGluR5 receptors. This broad receptor profile is consistent with a complex peptide mixture containing many different bioactive fragments.
PLAIN ENGLISH
When researchers test Cortexin on brain cells in a dish, they see effects on many different receptor systems—the kind of broad activity you would expect from a mixture containing dozens or hundreds of different peptide fragments. The problem is figuring out which fragments are doing what. Without that knowledge, you cannot optimize the dose, ensure batch consistency, or understand why the mixture works (if it does).
Molecular Partners
Proteomic analysis identified β5-tubulin, creatine kinase B, and protein 14-3-3 α/β as molecular partners of Cortexin peptides in brain tissue (PMID 30499504). This provides some mechanistic basis—β5-tubulin suggests microtubule interaction, creatine kinase B suggests energy metabolism modulation, and 14-3-3 proteins are ubiquitous signaling scaffolds. But these interactions were identified for the whole extract, not for individual peptides.
BBB Penetration
Mouse studies confirm that Cortexin components cross the blood-brain barrier—a necessary condition for CNS activity but not sufficient evidence of therapeutic efficacy.
Key Research Areas and Studies
Pediatric Cognitive Dysfunction
The largest Cortexin study is Chutko et al. (2018, PMID 29652302): a multicenter study of 635 children aged 3–7 years across four clinical groups (ADHD, speech delay, perinatal CNS lesion sequelae, asthenic/neurotic syndrome). Ten intramuscular Cortexin injections produced statistically significant improvement in cognitive function across all groups, with the best response in ADHD patients aged 3–4 years.
The critical limitation: This was an open-label study with no placebo control and no blinding. Every parent, child, and assessor knew the child was receiving treatment. In pediatric cognitive studies, this virtually guarantees positive results through placebo effect, regression to the mean, and natural developmental progress during the treatment period.
Post-Stroke Cognitive Recovery
An observational study of 30 young patients (18–45) with ischemic stroke showed MoCA scores improving from 25.1 to 28.4 after two Cortexin courses. Quality of life improved on SF-36. But N=30, open-label, and young stroke patients often recover cognitive function regardless of intervention.
Comparative Efficacy
Gusev et al. (PMID 18193579) compared Cortexin to piracetam (N=35) and Cerebrolysin (N=45) in acute ischemic stroke. Cortexin showed comparable efficacy to Cerebrolysin and superiority to piracetam. But this was non-randomized, small, and published in a Russian-language journal.
The Systematic Review Verdict
The 2021 systematic review (PMID 36324709) of animal-derived nootropics (Cerebrolysin, Actovegin, and Cortexin) found only one eligible Cortexin trial (N=80) that met basic methodological inclusion criteria. The review concluded: "supporting evidence is weak," effects are "probably less than would be considered clinically relevant," risk of bias is "moderate to high," and certainty of evidence is "low to very low."
The Khavinson Evidence Problem
Cortexin's evidence challenge is not unique to Cortexin—it is a structural problem that affects every product in the Khavinson bioregulator tradition. Understanding the pattern helps readers evaluate Cortexin and similar products.
The pattern: 1. A tissue extract is developed based on the bioregulation hypothesis. 2. Open-label clinical studies show improvement across multiple conditions. 3. The product achieves Russian regulatory approval and widespread clinical use. 4. When independent Western reviewers search for evidence meeting basic methodological standards (randomization, blinding, placebo control, adequate sample size), they find almost nothing.
This pattern has repeated for Cortexin, Thymalin, Epithalamin, and other bioregulators. It does not prove these products are ineffective—open-label studies in hundreds of patients are not worthless. But it does mean the evidence cannot distinguish between genuine therapeutic activity and the combined effects of placebo, regression to the mean, clinician enthusiasm, and natural recovery.
For Cortexin specifically, the gap between clinical use (millions of prescriptions across Russia) and rigorous evidence (one eligible trial with 80 patients) is one of the most dramatic in the entire nootropic space. This gap may reflect: (a) the product works but has never been properly tested; (b) the product does not work and its popularity reflects cultural and commercial factors; or (c) the product has modest effects that would be detectable in a properly powered trial but have never been measured by one. The honest answer is: we do not know which of these explanations is correct.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “"Improves cognitive function in children with ADHD"” | Chutko 2018 (N=635 children): improvement reported. But open-label, no placebo, no blinding. Systematic review: "weak evidence." | Mixed Evidence |
| “"Accelerates stroke recovery"” | Open-label study (N=30): MoCA improvement. Gusev comparison (N=80): comparable to Cerebrolysin. No placebo-controlled stroke trial. | Mixed Evidence |
| “"Neurotrophic—supports brain cell survival"” | Plausible from tissue-extract composition. Animal ischemia data: comparable to Cerebrolysin at lower doses. No identified active peptide. | Preclinical Only |
| “"Comparable to Cerebrolysin"” | Gusev comparative study and Khavinson 2021 animal data suggest comparable efficacy. But neither Cortexin nor Cerebrolysin has definitive human evidence. Comparable to a compound with its own evidence problems is not reassuring. | Mixed Evidence |
| “"Approved in Russia proves it works"” | Russian approval reflects different evidentiary standards. The 2021 systematic review could find only 1 eligible trial. Approval is not proof of efficacy. | Mixed Evidence |
| “"Safe and well-tolerated"” | No serious adverse events in published studies. Generally well-tolerated. But no systematic safety assessment. | Mixed Evidence |
| “"Modulates multiple brain receptors"” | In vitro data: AMPA, kainate, mGluR, GABA interactions. Attributed to the whole mixture, not identified peptides. | Preclinical Only |
| “"Helps with speech delay in children"” | Chutko 2018 included 215 children with speech delay—improvement reported. Open-label, uncontrolled. | Mixed Evidence |
| “"Anti-inflammatory neuroprotection"” | Animal ischemia models. No human neuroinflammation data. | Preclinical Only |
| “"Each batch is consistent"” | Standardized by manufacturing process, not by composition. No published batch-to-batch variability analysis. Tissue-derived mixtures inherently vary. | Unsupported |
| “"Crosses the blood-brain barrier"” | Confirmed in mouse studies. Necessary but not sufficient for efficacy. | Supported |
| “"Better than piracetam for stroke"” | Gusev comparative data (N=35 comparison): Cortexin superior. Non-randomized, very small. | Mixed Evidence |
We currently don’t have any vetted partners for this compound. Check back soon.
The Human Evidence Landscape
Chutko et al. (2018) — Multicenter Pediatric Study
Design: Multicenter, open-label, uncontrolled. N=635 children aged 3–7 years. ADHD (269), speech delay (215), perinatal CNS lesion sequelae (82), asthenic/neurotic syndrome (69). Ten IM Cortexin injections. PMID 29652302.
Findings: Statistically significant cognitive improvement across all groups. Best response in ADHD patients aged 3–4 years.
Limitations: No placebo. No blinding. Published in a low-impact journal. Children's cognitive development progresses naturally—without a control group, observed improvement cannot be attributed to Cortexin.
Post-Stroke Observational Study (2024/2025)
Design: Open prospective observational. N=30 patients aged 18–45 with ischemic stroke. Two Cortexin courses.
Findings: MoCA improvement from 25.1 ± 1.4 to 28.4 ± 1.3. Quality of life improvements on SF-36.
Limitations: N=30. No control group. Open-label. Young patients have better stroke recovery trajectories regardless of treatment.
Gusev et al. — Comparative Study
Design: Comparative (non-randomized). N=80. Cortexin vs. piracetam (35 patients); Cortexin vs. Cerebrolysin (45 patients) in acute ischemic stroke. PMID 18193579.
Findings: Cortexin showed comparable efficacy to Cerebrolysin and superiority to piracetam.
Limitations: Non-randomized. Russian-language. Small per-arm sample sizes.
2021 Systematic Review — The Independent Verdict
Design: Systematic review and meta-analysis of Cerebrolysin, Actovegin, and Cortexin. PMID 36324709.
Cortexin findings: Only one eligible trial (N=80) met inclusion criteria. "Data suggested potential efficacy and no safety concerns," but "the limited number of eligible studies precluded meta-analyses." Overall: "supporting evidence is weak," certainty "low to very low."
PLAIN ENGLISH
When an independent team tried to evaluate all the evidence for Cortexin, they found almost nothing that met basic scientific standards. Out of all the studies ever published, only one—with just 80 patients—was rigorous enough to include. That is an extraordinary gap for a product prescribed to millions.
Safety, Risks, and Limitations
Generally Well-Tolerated
Published studies report no serious adverse events. Injection site pain (IM administration) is the most common complaint.
No Systematic Safety Data
No adequately powered safety study has been conducted. The tolerability data comes from the same open-label, uncontrolled studies whose efficacy data is weak.
Batch Variability
As a tissue-derived extract, Cortexin's composition inherently varies with source tissue quality, processing conditions, and manufacturing lot. No published batch-to-batch consistency analysis exists.
Prion Risk
Bovine/porcine brain-derived products carry a theoretical prion disease risk. Manufacturing processes claim prion-inactivation steps, but the theoretical risk cannot be entirely eliminated for any brain-derived biological preparation.
No Drug Interaction Data
No formal drug interaction studies have been conducted.
CRITICAL DISCLAIMER
Cortexin is a brain-derived animal tissue extract. Individuals with known allergies to bovine or porcine products should exercise caution. The theoretical prion risk, while low, cannot be fully excluded for any brain-derived biological product.
Legal and Regulatory Status
Russia/CIS: Approved and widely prescribed for stroke rehabilitation, ADHD, pediatric neurodevelopmental disorders, and cognitive decline.
United States: Not approved. Not submitted. No IND filed. Legal status is research chemical or imported pharmaceutical.
European Union: Not approved.
Research Protocols and Formulation Considerations
Clinical Formulation
- Lyophilized powder in glass vials (10 mg per vial)
- Reconstituted with 1–2 mL of 0.9% sodium chloride or 0.5% procaine solution
- Administered by intramuscular injection
- Standard course: 10 daily injections, repeated as needed at intervals
Storage
Refrigeration required. Reconstituted solution should be used immediately.
Dosing in Published Research
Cortexin dosing is remarkably uniform across all published studies and Russian clinical practice: 10 mg by intramuscular injection, once daily, for 10-day courses. No dose-ranging studies have been published, and no intravenous formulation exists (unlike the related product Cerebrolysin). Courses are typically repeated at intervals of one to three months. The table below summarizes dosing from published clinical studies.
Published Clinical Dosing
| Indication | Dose | Route | Duration | Source |
|---|---|---|---|---|
| Pediatric cognitive dysfunction | 10 mg IM daily | Intramuscular | 10 days (1 course) | Chutko 2018 (PMID 29652302) |
| Post-stroke recovery | 10 mg IM daily | Intramuscular | 10 days × 2 courses | Observational study |
| Acute ischemic stroke | 10 mg IM daily | Intramuscular | 10 days | Gusev (PMID 18193579) |
Key Points
- Standard dosing across all indications: 10 mg IM daily for 10 days
- Courses are repeated at intervals (typically 1–3 months between courses)
- No dose-ranging studies have been published
- No IV formulation exists (unlike Cerebrolysin)
Dosing in Self-Experimentation Communities
WHY NO COMMUNITY DOSING SECTION?
Cortexin is an FDA-approved prescription medication. Dosing is established by clinical guidelines and managed by prescribing physicians. Community “dosing protocols” for prescription medications can be dangerous and are not appropriate to present here. Consult your healthcare provider for dosing information.
Cortexin is available from Russian pharmacy vendors and some nootropic suppliers. Community use follows Russian clinical practice: 10 mg IM daily for 10 days, repeated in courses. Some community members obtain pharmaceutical-grade Cortexin from Russian pharmacies; others use research chemical preparations of uncertain quality.
The intramuscular injection requirement limits Cortexin's popularity in the Western self-experimentation community compared to intranasally administered peptides (Semax, Selank) or orally bioavailable compounds (methylene blue). Community reports of effects include improved mental clarity, reduced brain fog, and enhanced recovery from cognitive fatigue.
CRITICAL DISCLAIMER
Cortexin is an animal brain-derived tissue extract. Product quality and composition may vary significantly between pharmaceutical-grade (Geropharm) and non-pharmaceutical sources. The theoretical prion risk exists for any brain-derived biological product from non-pharmaceutical manufacturers.
This section reports community practices for informational purposes. These protocols have not been validated in controlled trials.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into Cortexin combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining Cortexin with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
Frequently Asked Questions
What is Cortexin?
Cortexin is a mixture of small peptides and amino acids extracted from the brain tissue of cattle or pigs. It is manufactured by Geropharm in Russia and widely prescribed there for stroke recovery, ADHD in children, and cognitive decline. It is not a single defined drug—it is a tissue extract.
Is Cortexin FDA-approved?
No. Cortexin has never been submitted for FDA approval. It is approved and widely prescribed in Russia and CIS countries.
How is Cortexin different from Cerebrolysin?
Both are brain-derived peptide extracts. Cerebrolysin (EVER Neuro Pharma, Austria) uses whole porcine brain and has been tested in over 10,000 patients across 200+ studies. Cortexin (Geropharm, Russia) uses cerebral cortex specifically and has far less published evidence. Neither product's active ingredients have been identified.
Does Cortexin work for ADHD in children?
The largest study (635 children) reported cognitive improvements, but it was open-label with no placebo control. Without a control group, the observed improvement could be due to natural development, placebo effect, or expectation bias. The 2021 systematic review called the evidence \u0022weak.\u0022
Is there a risk of prion disease from Cortexin?
The theoretical risk exists with any animal brain-derived product. Geropharm's manufacturing process includes prion-inactivation steps, and no cases have been reported. But the risk cannot be entirely eliminated for biological products of brain origin.
Why did the systematic review find almost no evidence?
The 2021 review applied standard inclusion criteria (randomization, adequate controls, predefined endpoints). Most Cortexin studies are open-label without placebo groups. Only one study (N=80) met the minimum methodological bar. This reflects how the product was developed—through clinical practice observation rather than controlled trials.
What do we know about how Cortexin works?
Very little, definitively. In vitro studies show the extract interacts with multiple brain receptor systems (AMPA, kainate, GABA, mGluR). Proteomic analysis identified some molecular partners. But all of this is attributed to the whole mixture—no one has identified which specific peptides are responsible for which effects.
How is Cortexin administered?
By intramuscular injection. The lyophilized powder is reconstituted with saline and injected daily for ten-day courses. Unlike Cerebrolysin, there is no IV formulation.
Is Cortexin safe?
Published studies report no serious adverse events, and injection site pain is the main complaint. However, no systematic safety study has been conducted. The safety data comes from the same methodologically limited studies whose efficacy data is weak.
Can you take Cortexin orally?
No. As a mixture of peptides, Cortexin would be destroyed by digestive enzymes. All published evidence uses intramuscular injection.
What does the Khavinson bioregulator tradition mean?
Vladimir Khavinson's research program proposed that each organ produces specific regulatory peptides, and that extracting and administering these peptides can restore organ function. Cortexin is the brain cortex bioregulator. The tradition produced several products prescribed in Russia, but none have accumulated the rigorous evidence base that Western regulatory systems require.
What does \u0022Eyes Open\u0022 mean for Cortexin?
Eyes Open means \u0022proceed with caution—the evidence warrants attention but not confidence.\u0022 Cortexin earns this verdict because while it has biological plausibility and widespread clinical use in Russia, the independent systematic review found only weak evidence, and the gap between prescribing volume and evidence quality is one of the largest in the nootropic space.
Summary of Key Findings
Cortexin exemplifies a persistent tension in global medicine: a product can be prescribed to millions of patients in one regulatory system while having almost no evidence that would survive scrutiny in another. It is widely used in Russia for stroke recovery, ADHD in children, and cognitive decline. The 2021 systematic review found only one eligible trial and concluded the evidence is weak.
The biological plausibility is real—brain-derived peptide extracts could contain neurotrophic fragments, and the comparison to Cerebrolysin (which at least has a larger trial portfolio) suggests Cortexin may not be inert. But "may not be inert" is a low bar for a product injected into patients, including children.
The core problem is the one that defines all tissue-derived mixtures: undefined composition, unidentified active ingredients, and evidence generated primarily through uncontrolled observation rather than rigorous testing. Until a randomized, placebo-controlled trial with adequate statistical power is conducted, the question "does Cortexin work?" remains genuinely unanswered.
Verdict Recapitulation
Cortexin has widespread clinical use in Russia but minimal rigorous evidence. The systematic review verdict—"weak evidence," "low to very low certainty"—is the honest summary of what is known. The compound may have real biological activity, but the evidence to prove it does not yet exist. Eyes open—the prescription volume does not substitute for controlled evidence.
For readers considering Cortexin, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source Cortexin
Further Reading and Resources
If you want to go deeper on Cortexin, the evidence landscape for cognitive & neuroprotective peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Cognitive & Neuroprotective Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: Cortexin — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Chutko LS, Surushkina SYu, Yakovenko EA, et al. "Cortexin in the treatment of cognitive disorders in children." Journal of Neurological Sciences, MedCrave (2018). PMID 29652302
- Belskaya GN, Stepanova SB, Makarova LD, et al. "Cortexin in poststroke cognitive impairment in young patients." Neuroscience and Behavioral Physiology, 55, 353–356 (2024/2025)
- Ziganshina LE, Aboushaar MS, Wang Y, et al. "Cerebrolysin, Actovegin, and Cortexin: a systematic review." Cerebral Circulation — Cognition and Behavior, 3, 100147 (2022). PMID 36324709
- Gusev EI, Skvortsova VI, Chukanova EI. "Comparative neuroprotective efficacy of Cortexin and Cerebrolysin in acute ischemic stroke." Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 107(12), 24–29 (2007). PMID 18193579
- Khavinson VKh, Grigoriev EI, Malinin VV, et al. "Comparative neuroprotection of Cortexin, Cerebrolysin, and Actovegin in brain ischemia models." PLoS ONE, 16(7), e0254493 (2021). PMC8279368
- Krasnoperova MG, Koliukh OA, Morozova IN. "Molecular mechanisms of Cortexin: identification of molecular partners." Doklady Biological Sciences, 482(1), 192–195 (2018). PMID 30499504
- Khavinson VKh. "Peptide regulation of aging." Bulletin of Experimental Biology and Medicine, 137(1), 1–6 (2004)
DISCLAIMER
Cortexin is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 08, 2026. Next scheduled review: October 05, 2026.
About the Author
Lawrence Winnerman
Founder of Peptidings.com. Former big tech product manager. Independent peptide researcher focused on translating clinical evidence into accessible science.